Sun Pharmaceutical Industries' Founder and Managing Director Dilip Shanghvi has said the drugmaker was not involved in any insider trading norm violation in the Ranbaxy deal. "There was a minor technical issue relating to trading window closure norms," Shanghvi said. "The case was settled with SEBI without admission of guilt and the matter was closed," he added.